TNFA•benzinga•
TNF Pharmaceuticals Initiates Phase 2b Clinical Trial Of First Oral TNF-Alpha Inhibitor Candidate Isomyosamine For Treatment For Chronic Inflammation Associated With Muscle Loss In Patients Who Undergone Hip Or Femur Fracture Repair Surgery
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on February 25, 2025 by benzinga